(0.26%) 5 309.25 points
(0.28%) 38 901 points
(0.32%) 18 650 points
(-0.01%) $76.98
(4.48%) $2.70
(-0.09%) $2 343.60
(-0.11%) $30.41
(0.48%) $1 047.00
(0.02%) $0.921
(-0.02%) $10.48
(-0.01%) $0.785
(-0.46%) $90.02
@ $6.23
Issued: 14 Feb 2024 @ 15:20
Return: -17.50%
Previous signal: Feb 14 - 10:48
Previous signal:
Return: -7.02 %
Live Chart Being Loaded With Signals
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine...
Stats | |
---|---|
Today's Volume | 83 815.00 |
Average Volume | 329 515 |
Market Cap | 78.98M |
EPS | $0 ( 2024-05-28 ) |
Next earnings date | ( $-0.970 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0.0500 |
ATR14 | $0.0310 (0.60%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-09 | Cr Group L.p. | Buy | 108 752 | Common Stock |
2024-05-09 | Cr Group L.p. | Buy | 1 716 048 | Common Stock |
2024-05-09 | Cr Group L.p. | Sell | 17 160 | Series A Preferred Stock |
2024-05-09 | Cr Group L.p. | Sell | 10 875 | Series B Preferred Stock |
2024-05-03 | Cr Group L.p. | Buy | 1 565 445 | Common Stock |
INSIDER POWER |
---|
12.61 |
Last 99 transactions |
Buy: 59 163 264 | Sell: 43 265 399 |
Volume Correlation
T2 Biosystems Inc Correlation
10 Most Negative Correlations | |
---|---|
CRDF | -0.808 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
T2 Biosystems Inc Correlation - Currency/Commodity
T2 Biosystems Inc Financials
Annual | 2023 |
Revenue: | $7.19M |
Gross Profit: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2023 |
Revenue: | $7.19M |
Gross Profit: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2022 |
Revenue: | $22.31M |
Gross Profit: | $1.17M (5.23 %) |
EPS: | $-1 242.48 |
FY | 2021 |
Revenue: | $28.06M |
Gross Profit: | $7.36M (26.21 %) |
EPS: | $-20.29 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
T2 Biosystems Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators